Cargando…
Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels
DR4 (Death Receptor 4) and DR5 (Death Receptor 5) are two potential targets for cancer therapy due to their ability to trigger apoptosis of cancer cells, but not normal ones, when activated by their cognate ligand TRAIL (TNF related apoptosis-inducing ligand). Therapies based on soluble recombinant...
Autores principales: | Beyrath, Julien, Chekkat, Neila, Smulski, Cristian R., Lombardo, Caterina M., Lechner, Marie-Charlotte, Seguin, Cendrine, Decossas, Marion, Spanedda, Maria Vittoria, Frisch, Benoît, Guichard, Gilles, Fournel, Sylvie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323128/ https://www.ncbi.nlm.nih.gov/pubmed/27409341 http://dx.doi.org/10.18632/oncotarget.10508 |
Ejemplares similares
-
Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes
por: Chekkat, Neila, et al.
Publicado: (2018) -
Hetero-oligomerization between the TNF receptor superfamily members CD40, Fas and TRAILR2 modulate CD40 signalling
por: Smulski, Cristian R, et al.
Publicado: (2017) -
N-Heterocyclic Carbene-Polyethyleneimine (PEI) Platinum Complexes Inducing Human Cancer Cell Death: Polymer Carrier Impact
por: Wantz, May, et al.
Publicado: (2018) -
Smart tools and orthogonal click-like reactions onto small unilamellar vesicles: Additional molecular data
por: Vittoria Spanedda, Maria, et al.
Publicado: (2015) -
Toll-Like Receptor Agonists Synergize with CD40L to Induce Either Proliferation or Plasma Cell Differentiation of Mouse B Cells
por: Boeglin, Emmanuelle, et al.
Publicado: (2011)